pamidronate disodium

Phase 2Small molecule

NNational Cancer Institute (NCI)

pamidronate disodium is one of 62 small molecule programs targeting Avascular Necrosis. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Avascular NecrosisActive, not recruiting

SynovitisActive, not recruiting

Breast CancerActive, not recruiting

Multiple MyelomaActive, not recruiting

Avascular NecrosisPreclinical

Active, not recruiting

SynovitisPhase 1

Active, not recruiting

Breast CancerPhase 2

Active, not recruiting

Multiple MyelomaPhase 1

Active, not recruiting

Competition

Competitive Landscape

2828 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Halaven

Eisai

Preclinical

38 2

Nolvadex

SSan Diego Pacific Oncology & Hematology Associates

Preclinical

78 3

pamidronate disodium

NNational Cancer Institute (NCI)

Phase 2

1 4

Lexiscan

Astellas

Preclinical

1 5

Lupron

EEastern Cooperative Oncology Group

Preclinical

5 6

Chirocaine

PPurdue Pharma LP

Preclinical

1 7

Tricor

JJagotec

Preclinical

1 8

Cortef

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Preclinical

1 9

Vfend

PPrism Pharmaceuticals

Preclinical

—10

Apatinib Mesylate

BBukwang Pharmaceutical

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Multiple Myeloma3 trials

Arsenic Trioxide and Pamidronate in Treating Patients With Advanced Solid Tumors or Multiple Myeloma

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT00124605·24 enrolled

Combination Chemo, Peripheral Stem Cell Transplant, Biological Therapy, Pamidronate and Thalidomide for Multiple Myeloma

Completed·—·Phase 2·NCT00004088·77 enrolled

Dexamethasone With or Without Thalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma

Completed·NNational Cancer Institute (NCI)·Phase 3·NCT00033332

Breast Cancer1 trial

Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Women With Metastatic Breast Cancer

Completed·HHackensack Meridian Health·Phase 2·NCT00004906

Avascular Necrosis1 trial

The Use of Bisphosphonates in the Treatment of Avascular Necrosis of the Femoral Head

Terminated·TThe Hospital for Sick Children·N/A·NCT02007915·20 enrolled

Synovitis1 trial

Efficacy of Bisphosphonates in Patients With Synovitis, Acne, Pustulosis, Hyperostosis, and Osteitis (SAPHO) Syndrome

Completed·PPeking Union Medical College Hospital·Phase 1·NCT02544659·30 enrolled

Sources

References

[1]
ClinicalTrials.gov — 6 trial records for pamidronate disodium. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — pamidronate disodium compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for pamidronate disodium. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — National Cancer Institute (NCI) company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: NNational Cancer Institute (NCI)

pamidronate disodium

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Multiple Myeloma3 trials

Breast Cancer1 trial

Avascular Necrosis1 trial

Synovitis1 trial

References

Drug Info

Quick Facts

Related News